An interventional study of 3DV+TPS/VARIAN and TPS / VARIAN in Nasopharynx Cancer and Radiotherapy, sponsored by Xinqiao Hospital of Chongqing. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-02-23.
Sponsored by Xinqiao Hospital of Chongqing · Not applicable, Interventional, and Treatment
Verify that 3DV+TPS is non-inferior compared to existing imported TPS and superior to existing domestic TPS.
The main purpose of the study was to verify that 3DV+TPS is non-inferior compared to existing imported TPS and superior to existing domestic TPS. A total of 100 patients were enrolled. The primary endpoint of the study was the objective response rate (ORR), and the secondary endpoint was the local control rate and the incidence of treatment-related side effects.
816 studies on the registry are indexed under Nasopharyngeal Carcinoma; 282 are open to participants now.
This study's enrollment of 100 is above the median of 84 across 668 interventional studies indexed under Nasopharyngeal Carcinoma.
Browse Nasopharyngeal Carcinoma studies →Xinqiao Hospital of Chongqing is the lead sponsor of 68 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Use 3DV+TPS to map targets and develop treatment plans. The intervention is 3DV+TPS and VARIAN.
Device: 3DV+TPS/VARIAN
Use imported Varian TPS to map targets and develop treatment plans.
Device: TPS / VARIAN
Use 3DV+TPS to map targets and develop treatment plans.
Device: 3DV + TPS / Domestic Accelerator
Adopt domestic TPS hook target and develop treatment plan.
Device: TPS / Domestic Accelerator
Use imported 3DV+TPS to map targets and develop treatment plans
Use imported TPS to map targets and develop treatment plans
Use domestic 3DV+TPS to delineate target areas and develop treatment plans
Use domestic TPS to map targets and develop treatment plans
Objective response rate
Objective Remission Rate (ORR) is equal to complete remission (CR) + partial remission (PR)
Time frame: 3 months follow-up after treatment
Local control rate
Local control means that the tumor does not increase in imaging, but if the tumor does not increase, the patient with increased symptoms after treatment is not included in the local control range.
Time frame: 3 months follow-up after treatment
incidence of treatment-related side effects
Incidence of related side effects during disease treatment
Time frame: 3 months follow-up after treatment
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xinqiao Hospital of Chongqing